Heteroleptic oxidovanadium(V) complexes with activity against infective and non‐infective stages of trypanosoma cruzi

Abstract

Five heteroleptic compounds, [VVO(IN‐2H)(L‐H)], where L are 8‐hydroxyquinoline derivatives and IN is a Schiff base ligand, were synthesized and characterized in both the solid and solution state. The compounds were evaluated on epimastigotes and trypomastigotes of Trypanosoma cruzi as well as on VERO cells, as a mammalian cell model. Compounds showed activity against trypomastigotes with IC50 values of 0.29–3.02 μM. IN ligand and the new [VVO2(IN‐H)] complex showed negligible activity. The most active compound [VVO(IN‐2H)(L2‐H)], with L2 = 5‐chloro‐7‐ iodo‐8‐hydroxyquinoline, showed good selectivity towards the parasite and was selected to carry out further biological studies. Stability studies suggested a partial decomposition in solution. [VVO(IN‐2H)(L2‐H)] affects the infection potential of cell‐derived trypomastigotes. Low total vanadium uptake by parasites and preferential accumulation in the soluble proteins fraction were deter-mined. A trypanocide effect was observed when incubating epimastigotes with 10 × IC50 values of [VVO(IN‐2H)(L2‐H)] and the generation of ROS after treatments was suggested. Fluorescence com-petition measurements with DNA:ethidium bromide adduct showed a moderate DNA interaction of the complexes. In vivo toxicity study on C. elegans model showed no toxicity up to a 100 μM concentration of [VVO(IN‐2H)(L2‐H)]. This compound could be considered a prospective anti‐T. cruzi agent that deserves further research.